Screener
Organon OGN Arcoxia — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Clarinex | 1 | 30 | 31 | — | 34 | 34 |
| Other Respiratory (1) | 11 | 1 | 12 | 10 | 3 | 13 |
| Non-Opioid Pain, Bone and Dermatology | ||||||
| Arcoxia | — | 59 | 59 | — | 62 | 62 |
| Fosamax | — | 29 | 29 | 1 | 32 | 33 |
| Diprospan | — | 35 | 35 | — | 30 | 30 |
| Vtama | 23 | 2 | 25 | 20 | 4 | 24 |
| Other Non-Opioid Pain, Bone and Dermatology (1) | 3 | 65 | 68 | 4 | 65 | 68 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's arcoxia — revenue?
- Organon (OGN) reported arcoxia — revenue of $59M in Q1 2026.
- How has Organon's arcoxia — revenue changed year-over-year?
- Organon's arcoxia — revenue decreased by 4.8% year-over-year, from $62M to $59M.
- What is the long-term trend for Organon's arcoxia — revenue?
- Over 4 years (2021 to 2025), Organon's arcoxia — revenue has grown at a 2.3% compound annual growth rate (CAGR), from $243M to $266M.
- What does arcoxia — revenue mean?
- This metric represents the total gross revenue generated from the sale of the Arcoxia product line within the established medicines portfolio. It reflects the market demand and commercial performance of this specific therapeutic asset over a given fiscal period. Monitoring these revenues helps investors assess the lifecycle maturity and revenue stability of key legacy pharmaceutical products.
Ask your AI about Organon's arcoxia — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude